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Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a variable
incidence among different countries. Occupational asbestos exposure is the most
important etiological factor and a very long latency period is widely reported. In the
early phase of the disease, clinical signs are absent or not specific. For this reason,
the diagnosis is frequently achieved only in the advanced stages. The histopathological
diagnosis per se is also very complex, and no known factor can predict the prognosis with
certainty. Nonetheless, current survival rates remain very low, despite the use of standard
treatments, which include surgery, chemotherapy and radiotherapy. The identification of
new prognostic and/or diagnostic biomarkers, and the discovery of therapeutic targets
is a priority and could lead to a real significant impact on the management of malignant
pleural mesothelioma. In this scenario, the role of microRNAs is becoming increasingly
relevant, with the promise of a quick translation in the current clinical practice. Despite
the relative novelty of this field, the number of works and candidate microRNAs that are
present in literature is striking. Unfortunately, to date the microRNAs with the most clinical
relevance for MPM are still matter of debate, probably due to the variety of approaches,
techniques, and collected samples. Although specific microRNAs (e.g., let-7, miR-15 and
miR-16, miR-21, miR-34a, and the miR-200 family) have been reported several times
from different groups, the heterogeneity of published data reinforces the need of more
comprehensive and unified studies on this topic. In this review we collect and discuss
the studies focused on the involvement of microRNAs in different aspects of MPM, from
their biological role in tumorigenesis and progression, to their possible application as
diagnostic, prognostic and predictive biomarkers. Lastly, we examine their potential value
as for the design of therapeutic approaches that could benefit MPM patients.
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is a rare form of cancer originating from mesothelial cells
of the pleura and generally characterized by a poor prognosis. The highest incidence is reported
in the sixth and seventh decade of life. This tumor is more common in males than in females.
The overall survival (OS) is about 10 months for advanced disease, with a 5% 5-years survival rate.
Globally, MPM is responsible for 4% of cancer deaths in both men and women (1, 2).
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A cause-effect relationship to asbestos exposure is widely
reported, with symptoms that become often evident after a long
latency period. Because of this, a peak in the incidence of MPM
is awaited around 2030, due to the high exposure to asbestos in
past years in several countries (3). Other recognized risk factors
are radiation exposure, genetic mutations and the exposition to
Simian Virus 40 (4).
The most common subtype of MPM is the epithelioid subtype
(55–65%), followed by biphasic (15–20%), and sarcomatoid (10–
15%) forms (5). The median OS is strongly influenced by
histology, with lower survival rates for sarcomatoid patients in
comparison with epithelioid ones (6).
The diagnosis of MPM displays several layers of complexity.
Firstly, symptoms and imaging analyses are not disease-
specific. Moreover, the cytological examination of pleural fluid
is frequently possible only in advanced stages, and leads to
specific diagnosis in a minority of cases (7–9). Pleural biopsy
is the gold-standard diagnostic tool, but it can be affected by
adverse events like pleural bleeding, infections, empyema, and
pneumothorax (10). The histopathological diagnosis per se is
also very difficult because of the lack of immunohistochemical
markers with high specificity, and it requires the presence of a
particular combination of positive/negative markers evaluated by
an expert pathologist, especially when the goal is the differential
diagnosis of MPM subtypes (11, 12).
In recent decades, the identification of specific molecular
targets and genetic alterations has radically changed the
therapeutic paradigms for different types of cancer, but has not
significantly affected the natural history of MPM. In MPM both
the role of surgery and radiotherapy is controversial. Since 2003,
the only treatment that has clearly shown an improvement of
patients survival is the standard chemotherapy with platinum
and pemetrexed (13, 14). Both the use of different targeted
biological agents and immunotherapy with anti-CTLA4 did not
show a relevant efficacy even if many other checkpoint inhibitors
(anti-PD1/PD-L1) and new generation compounds are still being
investigated (13, 14).
In this difficult context, new prognostic or predictive
biomarkers, new diagnostic approaches, and therapeutic targets
are needed and could have a significant impact in the clinical
management of MPM. Among these, the role of microRNAs
(miRNAs) is becoming increasingly relevant. MiRNAs are small
non-coding RNAs of about 22 nucleotides, playing an important
role in post-transcriptional regulation of the expression of all
human genes. For this reason, miRNAs affect any cellular process,
including cell proliferation, apoptosis, and migration (15, 16).
Altered expression of specific miRNAs has been associated with
multiple human diseases, including cancer. Notably, differential
expression of miRNAs in healthy vs. cancer tissues of different
origins has been described, confirming the causal role of
miRNAs inmultiple aspects of cancer pathogenesis, ranging from
tumor establishment to progression, metastasis and resistance
to therapies (15, 16). Therefore, specific miRNA expression
signatures may correlate with different patient prognosis or
response to therapeutic approaches. Nonetheless, miRNAs can
be quantified in multiple biological fluids, such as blood,
cerebrospinal fluid, urine, and saliva. Also in these cases, specific
signatures for cancer vs. normal patients have been identified.
Altogether, these features make miRNAs ideal candidates as
prognostic, predictive and diagnostic biomarkers (16–18).
Finally, the modulation of miRNA expression, by inhibiting
those with oncogenic properties or rescuing the tumor-
suppressive ones, represents a new exciting topic in the
development of novel anti-cancer therapies (15–18).
The aim of this review is to describe the role of miRNAs in
MPM with a specific focus on the research state of the art and on
the potential translation in the current clinical practice.
BIOLOGICAL ROLES OF MIRNAS IN MPM
MiRNA Signatures
The first observations regarding the biological role of miRNAs
in MPM date back to 2009. Using miRNA microarray technique
(Agilent human miRNAs V2) and normal human pericardium
tissues as controls, Guled et al. demonstrated a different miRNA
expression profile between MPM and non-cancer tissues. By
analyzing 17 MPM samples and testing 723 miRNAs, they
showed a lower expression of let-7e, miR-7-1, miR-9, miR-34a,
miR-144, miR-203, miR-340, miR-423, miR-582, and a higher
expression of let-7b, miR-30b, miR-32, miR-195, miR-345, miR-
483-3p, miR-584, miR-595, miR-615-3p, miR-1228 in neoplastic
tissues compared with normal ones. The majority of these
miRNAs were either located in chromosomal areas generally
known as aberrant in MPM, or were targeting well-described
genes involved in MPM tumorigenesis. Over-expressed miR-30b,
miR-32, miR-483-3p, miR-584, and miR-885-3p target tumor-
suppressor genes such as CDKN2A, RB1, and NF2. Conversely,
down-regulated miR-9, miR-7-1, and miR-203 target EGF, HGF,
JUN, and PDGFA oncogenes (19).
Balatti et al. evaluated miRNA expression profile in 5 human
normal pleural mesothelial short-term cell cultures (HMCs)
and 5 MPM tissue samples, with microarray approach. The
comparative analysis of miRNA expression showed that miR-
17-92 cluster and its paralogs, called miR-17-5p, 18a, 19b,
20a, 20b, 25, 92, 106a, 106b, were strongly up-regulated.
Furthermore miR-7, miR-182, miR-214, and miR-497 were
showed to be dysregulated in MPM. Intriguingly, these miRNAs
were predicted (and later partially confirmed) to target genes
involved in the regulation of cell cycle progression (20).
Ramirez-Salazar et al analyzed, using PCR Array (384
miRNAs), specimens obtained from 4 patients with pleural
chronic inflammation, 5 patients with mesothelial hyperplasia,
5 patients with MPM and 4 normal controls with the aim
to identify tumorigenesis-related miRNAs and their biological
networks. MiR-101-3p and miR-494 were down-regulated in
pleural chronic inflammation and mesothelial hyperplasia,
respectively. In MPM tissues a reduction of miR-181a-5p, miR-
101-3p, miR-145-5p, and miR-212-3p expression was observed.
The down-regulation of these miRNAs resulted in increased
levels of the mesenchymal transition-associated molecule FZDA,
the transcription factor ETS1 and the signaling-activation
molecule MAPK1, which have strong oncogenic functions. This
suggested a possible association between pleural inflammation,
hyperplasia and tumorigenesis (21).
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Ak et al. also used PCR Array to compare miRNA signatures
in 18 MPM and 6 non-cancer pleural tissue samples obtained
from patients with benign asbestos-related pleural effusion.
The study found 11 over-expressed miRNAs in MPM (let-
7a, let-7d, miR-20a, miR-92a, miR-125a-5p, miR-152, miR-
155, miR-193b, miR-320, miR-484, and miR-744). The authors
further evaluated miRNA-mRNA interactions and found eight
significant pathways targeted by miRNAs, including two related
to NOTCH signaling. Compared to benign asbestos-related
pleural effusion,MET was the most overexpressed gene in MPM
(22).
In the study by Walter et al., NanoString technique was
used to evaluate expression of 800 miRNAs from 24 formalin-
fixed paraffin-embedded MPM samples. The principal aim was
to define the impact of miRNA expression on the MDM2-
P14/ARF (CDKN2A)-TP53 pathway, taking into account the
differential immunohistochemical MDM2 expression (score 0 vs.
score≥1) inMPM tissues. ElevenmiRNAs suppressingCDKN2A
(miR-29a, miR-29b, miR-29c, miR-125a, miR-125b, let-7a, let-
7c, let-7d, let-7e, let-7g, miR-340), 17 miRNAs inhibiting TP53
(miR-29a, miR-29b, miR-29c, miR-125a, miR-125b let-7a, let-
7c, let-7d, let-7e, let-7g miR-34a, miR-145, miR-185, miR-19b,
miR-218, miR-22, miR-27b) and 18 miRNAs targeting MDM2
(miR-29a, miR-29b, miR-29c, miR-125a, miR-125b miR-34a,
miR-145, miR-185, miR-140, miR-223, miR-23b, miR-142, miR-
191, miR-331, miR-605, miR-548d, miR-374b, miR-383) were
down-regulated in MDM2-expressing MPM. Since MDM2 and
CDKN2A expression regulates TP53 and may contribute to its
inactivation, the authors concluded that TP53 may be suppressed
bymiRNAs depending on expression pattern, whereas the impact
of miRNAs on CDKN2A and on MDM2 itself is mild (23).
Very recently, the same group published another paper based
on the same case series. In this work the authors focused their
attention on a small subset of miRNAs regulating key enzymes
involved in DNA damage repair. Specifically, the pathways
reported as mostly de-regulated were TP53 (let-7b-5p and miR-
143-3p), PARP1 (miR-21-5p, miR-223-3p, miR-302d-3p), and
RAD52 (miR-106a-5p, miR-106b-5p, miR-20a-5p) (24).
Lastly, Kim et al. investigated the global expression profile
of miRNAs in distinct subpopulations of a MPM cell line
(MS1). Their results showed that a subset of miRNAs is able to
define the most aggressive cell subpopulations. ErbB-2 receptor
tyrosine kinase signaling was the most involved pathway and
DDIT4 and ROCK2 the most involved target genes. The specific
miRNA signature defining aggressive subpopulations included
over-expression of miR-3198-1, miR-3198-2, miR-4497, miR-
138-1, miR-4304, miR-1281, miR-489, miR-4745, miR-301a, miR-
3935, and down-regulation of miR-148b, miR-484, miR-584,
miR-425, miR-197, miR-629, miR-183, miR-4485, miR-4443, and
miR-1246 (25).
Single miRNAs or miRNA Families
In regards to the role of single miRNAs or miRNA families in
the pathogenesis of MPM, a wide literature has been published to
date (Table 1) (26–42, 44–54).
Pass et al. analyzed 12 MPM cell lines (9 neoplastic and
3 normal) and 142 MPM tumor samples. In MPM cell lines,
the authors demonstrated that the over-expression of miR-
29c decrease invasion, migration, proliferation, and colony
formation. Furthermore, miR-29c over-expression mediated
epigenetic mechanisms through the down-regulation of DNMT1
andDNMT3A and the up-regulation of demethylating genes. The
increased level of miR-29c in tumor samples was related with a
better outcome after surgery. The authors hypothesized that miR-
29c could play a tumor suppressive role in MPM and thus it may
be a potential new therapeutic target (36).
Ivanov et al. reported that miR-31 plays a similar role in
MPM. The loss of expression of miR-31 due to the deletion of
miR-31 gene in chromosome 9p21.3 is a common aberration in
the aggressive forms of MPM. The investigators demonstrated
that miR-31 as well as miR-29c is able to block migration,
proliferation, and invasion in MPM cell lines. Moreover, low
miR-31 levels were associated with high levels of protein
phosphatase 6 (PPP6C) which were related with radio and
chemo-resistance. According to this study, the re-introduction of
miR-31 in MPM patients could be another potential therapeutic
approach (37).
One of themost studiedmiRNA family inMPM is represented
by miR-34 (38–42).
Ghawanmeh et al. examined the effects of docetaxel and
radiotherapy on MPM cell lines. In the M28K cells, radiotherapy
induced miR-34a expression, cell cycle arrest and cell death
(38). Kubo et al demonstrated that the epigenetic silencing of
miR34b/c due to methylation, is crucial in the pathogenesis of
MPM. In MPM cell lines the authors showed that physiologic
miR-34b/c levels had anti-proliferative effects and that the forced
over-expression of miR-34b/c had a pro-apoptotic effect (39).
The studies by Tanaka et al and by Maki et al confirmed these
observations (40, 41). The first article reported that the down-
regulation of miR-34a induced cell proliferation and invasion
in MPM cells because of the consequent up-regulation of c-
MET and BCL-2 (40). The second paper demonstrated that high
levels of miR-34b/c increased radiation-induced apoptosis and
suggested that miR-34b/c could be used as radiosensitizing agent
in MPM (41). Finally, Menges et al., proved in vivo that the
inactivation of CDKN2a and NF2 causes the development of
MPM in mouse models. These tumors were characterized by
TP53/miR-34a-dependent activation of c-MET, which correlated
with high aggressiveness and presence of cancer stem cells (42).
Some years after these studies, Yamamoto et al reported that
miR-379/411 cluster directly target IL-18 gene, whose over-
expression was associated with drug resistance in MPM cell lines.
In vitro, the introduction of miR-379 and miR-411 (with the
consequent IL-18 silencing) reduced invasiveness and increased
chemosesnsitivity of MPM cells (53).
A large body of evidence has demonstrated the role of
let-7 family in MPM pathogenesis. MiRNAs of this group
(including more than 10 different members) have all a similar
structure and have a huge number of functions and targets.
Firstly, Khodayari et al. showed that EphrinA1 signaling inhibits
MPM tumor growth by repressing RAS proto-oncogene family
through let-7a. EphrinA1 is a specific ligand of the EphrinA2
receptor, which is over-expressed in most cancer cells, including
MPM. In this work, the authors demonstrated that EphrinA1
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TABLE 1 | Biological roles of miRNAs in MPM.
miRNA Target genes/pathways Cell function References
miR-1 PIM1, TP53, BAX, P16/21, BCL2 Apoptosis, proliferation, migration, invasion (26, 27)
Let-7a/b EphA1 signaling, RAS, PARP,
Procaspases 3, Twist, b-catenin, AKT,
TP53
EMT, apoptosis, proliferation, migration, invasion (23, 24, 28–30)
miR-15a/16 BCL-2, CCDN1, PD-L1, FGF axis Radio/chemo-sensitivity, apoptosis, proliferation, colony
formation
(31–33)
miR-17-5p KCNMA1 Migration (34)
miR-21-5p PARP1, MSLN Proliferation (24, 35)
miR-29c-5p TP53, DNMT1, DNMT3A Methylation, proliferation, colony formation, migration,
invasion
(23, 24, 36)
miR-31 PPP6C Radio/chemo-sensitivity, proliferation, colony formation,
migration, invasion
(37)
miR-34a/b/c BCL-2, c-MET, CDKN2A, NF2, TP53 Radio/chemo-sensitivity, apoptosis, methylation, proliferation,
colony formation, migration, invasion
(38–43)
miR-126 ACL, PDK, IRS1, HIF1α, EGFL7 Autophagic flux, mitochondrial function, methylation,
proliferation, migration, invasion
(44–46)
miR-137 YBX1 Proliferation, migration, invasion, (47)
miR-145 OCT4, ZEB1 Proliferation, migration, invasion, colony formation, (48)
miR-193a-3p MCL1, PD-L1 Apoptosis, cell death, proliferation (49)
miR-205 ZEB1, ZEB2 EMT, migration, invasion (50)
miR-223 PARP1, MDM2, TP53, JNK signaling,
STMN1
Tubulin acethylation, proliferation, migration (23, 24, 51)
miR-302b MCL1 Apoptosis, proliferation (52)
miR-379, miR-411 IL-18 Chemo-sensitivity, proliferation, invasion (53)
binding to its receptor EphrinA2 suppresses MPM tumor growth
through up-regulation of miR let-7a and the subsequent down-
regulation of RAS proto-oncogenes family (28). Two years later
the same group reported that the targeted delivery of miR let-
7a, encapsulated in liposomal nanoparticles conjugated with
EphrinA1, inhibits migration, proliferation, and tumor growth
in MPM and NSCLC cell lines. This observation suggests a
new possible therapeutic approach potentially useful especially in
neoplasms overexpressing EphrinA2 receptor (29).
Sohn et al. focused their attention on another member of let-
7 family. By transfecting let-7b synthetic mimic in H28, H2452,
and MSTO-211H MPM cell lines treated with ursolic acid, they
found that the up-regulation of let-7b was critically involved
in ursolic acid induced apoptosis. The over-expression of let-7b
increased the activity of ursolic acid leading to PARP and caspase
3 cleavage, and down-regulation of Twist, β-catenin and pAKT
with a consequential sub-G1 cell accumulation and block of the
epithelial to mesenchymal transition (EMT) (30).
In regards to the role of EMT in MPM pathogenesis, Fassina
et al. have given an important contribution. They collected
109 MPM tissue samples (58 epithelioid, 25 biphasic, and 26
sarcomatoid) and showed that there is a switch in the expression
from epithelial to mesenchymal markers going through the less
aggressive epithelioid forms to the more aggressive biphasic and
sarcomatoid histotypes. Moreover, overexpression of miR-205 in
mesothelial (MeT-5A) and MPM cell lines (H2452 and MSTO-
211H) caused a reduction in the expression of mesenchymal
(ZEB1 and ZEB2) and an increment of epithelial (E-cadherin)
markers, which ultimately led to the inhibition of migration and
invasion processes (50).
Using microarray transcriptional profiling and having normal
pleural tissue as control, Xu et al. analyzed 25 MPM tissue
samples and found lower miR-1 levels in neoplastic tissues.
Accordingly, reduced proliferation and increased apoptosis of
MPM cell lines (H513 and H2052) upon overexpression of miR-
1 was observed. This suggests that miR-1 may act as tumor
suppressor in MPM (26). These data were confirmed in the
subsequent study by Amatya et al, where transfection of miR-1
and miR-214 mimic led to the down-regulation of the proto-
oncogene PIM1 and to the inhibition of cell growth, invasion and
migration (27).
Reid et al. firstly showed that miR-15/16 family is down-
regulated in MPM tumor tissues and cell lines, and has a tumor
suppressive role in MPM. In their experience, restoring miR-
15/16 expression in MPM cell lines caused a reduction of cell
proliferation and increased chemosensitivity. These phenomena
were correlated with the down-regulation of specific genes
such as CCND1 and BCL-2. Using xenografts models, the
authors described a relevant antitumoral activity for miR-16
mimic packaged in intravenously-administered “minicells” (31).
Very recently, the same group demonstrated that miR-15a,
miR-16, and also miR-193a-3p contribute to the regulation of
programmed death ligand 1 (PD-L1) expression inMPM causing
its down-regulation (32). Moreover, Schelch et al. observed
a down-regulation of the fibroblast growth factor (FGF) axis
after transfection with miR-15/16 mimics. The restoration of
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miR-15/16 caused growth reduction in MPM cell lines and
the combined inhibition of BCL-2 (another miR-15/16 target)
resulted in a synergistic activity (33).
Cioce et al. focused their attention on miR-145, showing that
treatment of MPM cell lines with miR-145 agonists reduced the
protumorigenic power of MPM cells and increased the sensibility
to pemetrexed. These data were confirmed in animal models, in
which restoration ofmiR-145 expression inhibited tumor growth.
The authors found that miR-145 targetedOCT4 reducing its level
and the level of its transcriptional target ZEB1. Higher OCT4
levels were associated with resistance to chemotherapy and with
tumor growth (48).
As described by Tomasetti et al., miR-126 displays an
oncosuppressive role in MPM cells by targeting IRS1, leading to
impairedmitochondrial function and cell growth.Moreover, they
demonstrated that miR-126 initiates a metabolic program, which
implies high autophagic flux and HIF1α stabilization, playing
a protective role in MPM (44, 45). Andersen et al., analyzing
MPM tumor tissues and non-neoplastic controls, showed that
DNA-hypermethylation down-regulates miR-126 and its host
gene EGFL7 leading to a reduction in patients survival in MPM
(46).
Birnie et al. identified reduced levels of miR-223 in MPM
patient specimens. The authors demonstrated that miR-223
targets STMN1, a microtubule regulator that has been associated
with MPM. Moreover, they displayed that STMN1 is also
regulated by the JNK signaling. The overexpression of miR-223
in MPM cell lines reduced STMN1 levels with a consequential
induction of tubulin acetylation and reduction of cell motility.
Furthermore, miR-223 levels grew and STMN1 levels decreased
after the re-expression of the JNK isoforms in JNK-null murine
embryonic fibroblasts. Finally, STMN1 levels decreased after JNK
signaling activation (51). As reported by Walter et al., miR-223
is also down-regulated in MPM expressing MDM2, a negative
regulator of TP53 (23).
Williams et al. found a significant decrease of the levels of
miR-192 and miR-193a-3p in MPM tumor samples compared
with non-cancer tissues. In MPM cell lines, transfection of miR-
193a-3p mimic induced apoptosis and reduced cell proliferation
causing reduction of the expression of the anti-apoptotic protein
MCL1, frequently over-expressed in MPM. These data were
confirmed in xenograft models in which the use of minicells
containing miR-193a-3p mimics reduced tumor growth and
increased apoptosis (49). In MPM, MCL1 is also downregulated
by miR-302b. Khodayari et al. demonstrated that the treatment
with ephrinA1 leads to the over-expression of miR-302b, which
inhibits MCL-1 expression with a consequential induction of
apoptosis and reduction of cells proliferation (52).
Cheng et al demonstrated that KCa1.1, a calcium-activated
potassium channel subunit alpha 1 encoded by the KCNMA1
gene, is a target of miR-17-5p. KCa1.1 was overexpressed in
MPM cells lines and MPM tissues compared with non-cancer
samples. Moreover, the transfection of MPM cells with miR-17-
5p mimic reduced the expression of KCa1.1 and blocked MPM
cells migration (34).
De Santi et al., using Next Generation Sequencing (NGS)
and the “miR-CATCH” method (based on biotinylated DNA
antisense oligonucleotides that capture mRNA), identified miR-
21-5p as a functional regulator of mesothelin (MSLN) gene
expression. Moreover, they demonstrated that treatment with
miR-21-5p mimic may decrease the proliferation in MPM cell
lines (35). In a different study, the same group suggested that
miR-126, miR-15b, miR-145, miR-185, miR-197, and miR-299
play a role in the regulation of cell metabolism in MPM.
Comparing miRNA expression profile of 96 MPM patients with
10 non-cancer controls they found a significant down-regulation
of these miRNAs in MPM. The top five pathways significantly
affected by the deregulated miRNAs were: fatty acid biosynthesis,
focal adhesion, MAPK, P53, and WNT signaling pathway (54).
Finally, few months before the submission of our review,
Johnson et al., using MPM cell lines,127 MPM tissue samples (3
different cohorts), and 23 pleural or pericardium tissue controls,
showed that miR-137 can exhibit a tumor-suppressive role in
MPM by targeting Y-box binding protein 1 (YBX1). YBX1
knockdown significantly reduces tumor growth, migration, and
invasion of MPM cells (47).
TISSUE EXPRESSION OF MIRNAS AS
PROGNOSTIC AND DIAGNOSTIC
BIOMARKERS IN MPM
The previously cited paper by Pass et al is the first work proposing
microRNAs as potential prognostic biomarkers in MPM. Using
a custom miRNA expression analysis platform, a training set of
44 and a test set of 98 MPM tumor samples were analyzed. In
both training and test sets, higher levels of tissue miR-29c was
shown to be an independent prognostic factor for higher OS
and time to progression (TTP) after surgery (36). Using qRT-
PCR, Matsumoto et al measured miR-31 expression in 25 tissue
samples obtained fromMPMpatients and in 20 tissues of patients
with reactive mesothelial proliferations (RMPs). They displayed
that the expression of miR-31 was reduced in MPM compared
with RMPs. However, the up-regulation of miR-31 was associated
with the presence of sarcomatoid component and with worse
prognosis in patients affected by this histological tumor sub-
type (55). Likewise, in the study by Busacca et al., low cancer
tissue levels of miR-17-5p and miR-30c were associated with
better OS in sarcomatoid MPM patients. Moreover, miR-30c was
described as differentially expressed in the three MPM histotypes
(56). Lastly, in the study by Fassina et al., the tissue levels of
miR-205 were reported as lower in the more aggressive biphasic
and sarcomatoid MPM histotypes and higher in the epithelioid
forms characterized by better prognosis (50). Obviously, all these
studies also suggest a role of miR-31, miR-17-5p, miR-30c, and
miR-205 in the differential histopathological diagnosis of MPM.
The prognostic role of miRNAs in MPM has been
demonstrated by different other studies (Tables 2–4)
(24, 47, 54, 73–75, 78, 79).
In particular: highmiR-137 (47) andmiR-1, miR-335-5p,miR-
566 (24) tissue levels have been correlated to poor prognosis,
while the high tissue expression of miR-146a-5p, miR-378a-3p,
miR-451a, miR-1246 (24), and of miR-16, miR-486 (75) was
positively related with a better outcome.
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Kirschner et al. identified a 6-miRNA signature (miR-
Score) predictive of higher OS in patients with MPM who
underwent extrapleural pneumonectomy with or without
induction chemotherapy, including miR-21-5p, miR-23a-3p,
miR-30e-5p, miR-221-3p, miR-222-3p, and miR-31-5p.14 (73).
The 6-miR-Score has been subsequently modified first into a 2-
miR-Score for use in diagnostic chemo-naïve specimens (78),
than in a combined 2-miRNA-clinical score prognostic in both
chemo-naïve and treated patients (79). The 2-miR-Score includes
miR-221-3p.
De Santi et al. also identified a 2-miRNA prognostic signature.
In the 52 MPM tissue samples analyzed, higher levels of let-7c-
5p and miR-151a-5p were associated with poorer OS. These data
were confirmed in a second cohort of 16 fresh/ frozen MPM (54).
Finally, using a microarray platform and 27 tissue samples
obtained from un-resectedMPMpatients, Truini et al. performed
a whole miRNA profiling and selected mir-99a, let-7c, and miR-
125b as potential prognostic miRNAs. The signature was tested
on public miRNA sequencing data from 72 MPM patients with
available OS and validated by RT-qPCR in an independent set of
30MPM patients. The authors found that the down-regulation of
the miR-99a/let-7/miR-125b miRNA cluster was able to predict
poor outcome in unresected MPM (74).
In regards to the potential role of miRNA tissue expression
as diagnostic biomarkers, a large number of studies have been
published (Tables 2–4) (19–22, 26, 27, 48, 51, 57–60).
Guled et al. identified specific miRNA profiles in tumor and
non-cancer tissues, associated with specific histopathological
subtypes (19).
Using microarrays, Benjamin et al. identified a different
miRNA tissue expression profile between different types of
cancer and MPM. MiR-193-3p levels were higher in MPM,
while miR-192 and miR-200c levels were higher in lung primary
adenocarcinomas and pleural metastases. In a blinded validation
set of 68 samples the assay had a specificity of 94% and a
sensitivity of 100% (57).
With the aim to identify amiRNA signature able to distinguish
between MPM and lung adenocarcinoma, Gee et al., using
microarrays, analyzed 15 MPM and 10 lung adenocarcinoma
tissue samples. The results were validated by RT-qPCR in 32
lung adenocarcinoma and 100 MPM samples, respectively. MiR-
141, miR-200b, miR-200c, miR-203, miR-205, and miR-429 were
down-expressed in MPM and resulted able to discriminate MPM
from lung adenocarcinoma (58).
Santarelli et al. tested fresh or frozen biopsies of MPM for the
expression of 88 miRNAs and compared the results with non-
cancer tissue controls. They found that miR-126 was significantly
down-regulated in neoplastic tissues (60).
Ak et al. showed a significant up-regulation of multiple
miRNAs in MPM tissue samples, and demonstrated that let-7a,
miR-125a-5p, miR-320, and miR-484, were able to discriminate
MPM from benign asbestos related diseases (22).
Andersen et al. demonstrated a potential diagnostic value
of miR-126, miR-143, miR-145, and miR-652 in MPM. They
screened with a (RT-qPCR)-based platform the expression of 742
miRNAs in 5 MPM tissue samples of patients previously treated
with chemotherapy, 5 preoperative diagnostic biopsies of patients
with MPM and 5 non-neoplastic pleura samples obtained from
patients with MPM diagnosis after chemotherapy treatment. The
author showed that miR-126, miR-143, miR-145, and miR-652
levels were significantly reduced inMPM samples compared with
non-cancer pleural tissues. The results were validated by RT-
qPCR in a cohort of 40 independent MPMs. However, we have
to take into account that chemotherapy may induce changes in
the miRNA expression both in neoplastic and non-cancer tissues
and this is the biggest limitation of this study (59).
EXPRESSION OF MIRNAS IN PLEURAL
EFFUSION
The detection and the quantification of miRNAs in pleural
effusion cells have a great potential for the identification of new
minimally-invasive diagnostic biomarker (Tables 2–4).
Firstly Birnie et al., using RT-qPCR, showed that in
comparison with non-cancer specimens, miR-223 levels were
significantly reduced both in the cellular component of the
pleural effusion of MPM patients and in MPM tissue samples.
They compared 6 non-neoplastic with 17 neoplastic tissue
samples and 10 pleural effusion specimens obtained from
patients with benign pleural diseases with 26 coming from MPM
patients (51).
In a first work from Cappellesso et al., analyzed the expression
of 15 selected miRNAs in one normal mesothelial (MeT-5A) and
two neoplastic (H2052 and H28) MPM cell lines using RT-qPCR.
MiRNAs were also tested in 51 MPM and 40 non-neoplastic
pleural tissue samples, and validated in 29 neoplastic and 24
non-neoplastic pleural effusion cytologic specimens. Compared
with non-neoplastic controls, miR-19a, miR-19b, and miR-21
were over-expressed, andmiR-126 was under-expressed in tumor
samples. The authors concluded that miRNAs were detectable in
the cytologic component of MPM pleural effusion, and especially
the combination of miR-21 and miR-126 could be useful in the
MPM diagnosis, reporting 86% sensitivity and 87% specificity
(61).
In a second study, the authors investigated the significance
of miRNAs in the differential diagnosis between lung
adenocarcinoma and MPM pleural effusion. A pool of selected
miRNAs was analyzed by RT-qPCR in 41 vs. 40 tissue samples
and in 26 vs. 27 cytological pleural effusion specimens obtained
from MPM and lung adenocarcinoma patients, respectively. The
authors showed that miR-130a, miR-141, miR-193a, miR-205,
miR-375, and miR-675 were differentially expressed in the two
tumors, but only miR-130a was significantly overexpressed in
MPM compared with lung adenocarcinoma. The sensitivity
and specificity of miR-130a quantification in the differential
diagnosis were 77 and 67%, respectively (62).
MIRNA EXPRESSION IN SERUM, PLASMA
AND CELLULAR FRACTION OF BLOOD
It has been demonstrated that miRNAs are secreted in blood
and serum, where they can be found both as soluble/protein
associated, or included in lipid vesicles such as exosomes.
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For mechanisms that are still not completely known, cancer
cells release a higher amount of circulating miRNAs, whose
composition reflects the one present in the secreting cells. For this
reason, the detection and quantification of circulating cancer-
derived miRNAs might represent an extremely valuable tool
for the management of different tumor types, including MPM
(Tables 2–4) (15–18).
Using RT-qPCR Santarelli et al. compared the serum levels
of miR-126 obtained from 50 healthy controls, 196 asbestos-
exposed, and 44 MPM patients. The authors reported that cut-
off values of miR-126 could significantly differentiate asbestos-
exposed subjects from healthy controls and from MPM group.
Moreover, the association between low levels of miR-126 and
high levels of the specific MPM markers such as soluble
mesothelin-related peptides (SMRPs) was able to identify subjects
with high risk to develop MPM (60).
One year later the same group published another paper
with the aim to investigate the accuracy and precision of
circulating miR-126 quantification as clinical biomarker. The
authors evaluated miR-126 serum levels in 56 healthy subjects,
20 non-small-cell lung cancer and 45 MPM patients, using both
absolute and relative qRT-PCR methods. MiR-126 serum levels
were reduced in both tumor types and associated with worse
prognosis in MPM. Moreover, the quantification of miR-126
differentiated MPM from both normal controls and non-small-
cell lung cancer, but it was not able to discriminate healthy
controls from non-small-cell lung cancer (76).
In a third paper, Santarelli et al. combined the quantification
of circulating miR-126 with SMRPs and methylated
thrombomodulin promoter (Met-TM) serum determination. A
total of 44 healthy controls, 99 asbestos-exposed, and 44 MPM
patients were evaluated. The combination of high SMRP and
Met-TM levels with low levels of miR-16 was evaluated as the
best method to distinguish MPM from the other two groups.
Moreover, in non-neoplastic subjects, the association between
high SMRP levels and high Met-TM or low miR-16 levels,
increased significantly the MPM risk. These data were confirmed
in a validation cohort of 20 healthy controls, 50 asbestos-exposed
subjects, 18 MPM, and 42 lung cancer patients (63).
With the aim to discriminate between lung adenocarcinoma
and MPM diagnosis, Gayosso-Gómez et al. studied miRNA
profile of serum samples obtained from healthy subjects (N =
45), lung adenocarcinoma (N = 36), andMPMpatients (N = 11).
Among knownmiRNAs, in comparison with normal controls, 12
miRNAs were overexpressed in lung adenocarcinoma, and 7 in
MPM. Three of these were up-regulated only in MPM (miR-92b-
5p, miR-409-5, and miR-1292). These differences could be very
useful in the differential diagnosis process (64).
The potential role of increased circulating levels of miR-625-
3p as biomarker for MPM has been showed by Kirschner et al.
Firstly, using microarray analyses, the authors tested 90 miRNAs
previously reported as associated with MPM in plasma samples
of a cohort of 5 MPM patients and 3 healthy subjects, and
found 15 miRNAs with higher levels in MPM patients compared
with controls. Using qRT-PCR, the results were validated in
a second cohort of plasma samples obtained from 14 non-
neoplastic subjects and 15MPM patients, and in a third cohort of
serum samples obtained from 10 patients with asbestosis and 30
with MPM. In the three cohorts, only the high concentration of
miR-625-3p was always able to discriminate between MPM and
non-MPM patients. The up-regulation of miR-625-3p in MPM
was also confirmed in a forth cohort of tissue samples (6 normal
pericardial and 18 MPM tissues) (65).
Lamberti et al. collected serum samples from 14 patients with
MPM and 10 patients affected by non-cancer-related pleural
effusions, and performed a miRNA profiling using low-density
microarray Real Time PCR system. They found two miRNAs
exclusively expressed (miR-516 and miR-29a), two miRNAs
down-regulated (miR-223 and miR-191), and five miRNAs up-
regulated (miR-335, miR-25, miR-26b, miR-101, and miR-433)
in MPM samples compared with non-cancer controls. Patients
with MPM were divided into two miRNA serum signature
groups: signature A (patients with more than 3/9 up-regulated
miRNAs or 3/9 up-regulated miRNAs and miR-516 unchanged
or not recordable) and signature B (patients with at least 3/9
down-regulated or unchanged miRNAs and/or miR-29a down-
regulated). MPM patients with signature B had longer OS in
comparison with patients with signature A (17 vs. 7 months).
The authors also reported that signature A was associated with
sarcomatoid or biphasic histology (5/5 patients), nevertheless
they did not report the statistical value. However, this study
displayed the limitations of a low number of patients enrolled
and the use of patients with pleural effusions as controls instead
of healthy subjects (77).
In the study by Bononi et al., serum circulating miRNAs from
10 healthy subjects, 10 asbestos-exposed and 10 MPM patients
were analyzed with microarray and validated by qRT-PCR in a
second cohort of 14 healthy controls, 15 asbestos-exposed, and
20 MPM patients (30 serum samples were previously used for
microarray analysis). In MPM patients they found up-regulation
ofmiR-1281 in comparison to both healthy subjects and asbestos-
exposed patients, up-regulation of miR-32-3p and miR-197-3p in
comparison only to asbestos-exposed patients and up-regulation
of miR-32-3p, miR-197-3p, and miR-1281 in comparison only to
healthy subjects. The authors concluded that these three miRNAs
could be proposed as new MPM diagnostic biomarker (66).
Weber et al used TaqMan Low Density Array Human
MicroRNA Cards to analyze 377 miRNAs in plasma samples
obtained from 21 asbestos-exposed and 21 MPM patients. The
results were validated in a second cohort of 44 asbestos-exposed
and 22 MPM patients using RT-qPCR. The authors showed
that miR-132-3p was significantly down-regulated in MPM and
only this miRNA resulted able to well discriminate between
MPM and asbestos-exposed patients with a reported specificity
of 61% and sensitivity of 86%. MiR-126 was also reported as
down-regulated in MPM but only in the validation cohort. The
authors calculated a specificity of 86% and a sensitivity of 77%
for the combined down-regulation of the two miRNAs used as
diagnostic biomarker. Nevertheless, it is not clear why miR-126
was not reported as down-regulated also in the discovery cohort
of this study (67).
Mozzoni et al. aimed to identify a miRNA signature helpful
as diagnostic biomarker for asbestos-exposed andMPM patients.
The authors collected tissue and plasma samples from patients
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affected by MPM (32 cases), asbestosis (14 cases), and other non-
cancer pulmonary diseases (15 cases, used as controls). MiR-
16, miR-17, miR-126, and miR-486 levels were quantified in
plasma and tissues using qRT-PCR and all resulted decreased
both in patients with asbestosis and in MPM, compared to
controls. The levels of miR-486, miR-17, and miR-16 were
significantly correlated in MPM tissue and plasma samples.
Moreover, the tissue expression of miR-16 and miR-486 and
the plasma levels of miRNA-16 were positively related with
OS (75).
Lastly, Matboli et al., in a very recent paper, showed that
the quantification of serum miR-548a-3p and miR-20a levels
is a promising new diagnostic tool in MPM management.
MiR-20a and miR-548a-3p were assessed in sera of healthy
controls, asbestos-exposed and MPM patients using qRT-PCR.
Their expression was positive in 91.6 and 96.7% MPM cases
respectively, with a 100% of sensitivity as diagnostic MPM
biomarker when used in combination (68).
Diagnostic approaches very different from those described
above in this section have been used in some other works (69–72).
The epigenetic silencing of miR-34b/c plays a crucial role in
the pathogenesis of MPM and in about 90% of MPM cases miR-
34b/c is downregulated by DNAmethylation (39). Using a digital
methylation specific PCR assay, Muraoka et al. analyzed serum
samples of 41 healthy controls, 21 asbestos-exposed and 48MPM
patients and demonstrated that a high degree of methylation of
miR-34b/c in serum-circulating DNA is associated with MPM
diagnosis and with higher MPM stage in patients with previous
MPM diagnosis (72).
Cavalleri et al., using an OpenArray method, investigated
the expression of 754 miRNAs in the plasmatic extracellular
vesicles of 19 asbestos-exposed and 23 MPM patients, and
found 55 differentially expressed miRNAs. Among these, 16 were
confirmed by RT-qPCR in the validation phase. MiR-30e-3p,
miR-98, miR-103a-3p, miR-148b, and miR-744 were the best
discriminating miRNAs, and the combination of miR-30e-3p and
miR-103a-3p was reported as the most discriminating one with
a specificity of 80.0% and a sensitivity of 95.5%. This study is
the only one using miRNA quantification in plasma exosomes.
This new diagnostic approach is very interesting because it
may provide a huge number of information about miRNA
release mechanisms but it has the disadvantage of being very
expensive (69).
The role of miR-103 family as diagnostic biomarker has been
previously shown also by Weber et al. In two consecutive works,
the authors used a totally different diagnostic technique based on
the identification and quantification of miRNAs in the cellular
fraction of human peripheral blood (70, 71). In the first pilot
study, published on 2012, the investigators enrolled 17 asbestos-
exposed and 23MPM patients. Analyzing a panel of 328 miRNAs
with microarrays, they found the low expression of miR-20a and
miR-103. Quantitative-RT-PCR was used for validation phase in
25 healthy subjects, 17 asbestos-exposed and 23 MPM patients
and confirmed only miR-103 as significantly down-expressed
in the cellular fraction of MPM patients’ blood. The authors
calculated a specificity of 76% with a sensitivity of 78%, and a
specificity of 71% with a sensitivity of 83% for the discrimination
ofMPM from healthy and asbestos-exposed subjects, respectively
(70).
In the second study, the authors evaluated the performance of
the combination of miR-103a-3p and mesothelin quantification
as diagnostic biomarker in MPM. The analysis was performed
on 52 asbestos-exposed and 43 MPM male patients. Mesothelin
concentration was determined in plasma samples using ELISA
test whilst the levels of miR-103a-3p was assessed in the blood
cellular fraction using RT-qPCR. For the discrimination between
asbestos-exposed and MPM patients miR-103a-3p, mesothelin
and the combination of both showed 89, 74, 95% and 63, 85, 81%
of sensitivity and specificity, respectively (71).
POTENTIAL THERAPEUTIC ROLE
Since their discovery, miRNAs have always been considered
as one of the most interesting therapeutic prospects for
cancer treatment. Their ability to target multiple cell pathways
and the important regulatory role they play in almost
all the mechanisms underlying cell replication and tumor
progression, have made scientists to believe that they could
be widely exploited to increase anti-tumor response and to
reduce drug resistance. Considering that a huge number
of miRNAs are down-regulated in many cancer types, the
great part of the tested therapeutic strategies are based
on the possibility to restoring the miRNAs function, often
through the delivery of the down-expressed miRNAs inside
the tumor cell. In MPM this new therapeutic approach has
been experimented in cell lines and mouse models. Various
miRNAs (let-7a, miR-16, miR-34b-c, miR-126, mir-145, miR-
193a-3p) and various delivery systems have been tested
obtaining interesting results in terms of tumor growth inhibition
(29, 31, 33, 42–44, 48, 49).
However, despite these interesting premises, to date the
results of only one clinical trial (NCT02369198) are available
in human subjects. In this phase I, open-label, dose-escalation
study, the authors aimed to investigate the safety, the optimal
dose and the activity of TargomiRs in MPM patients. TargomiRs
are minicells (EnGeneIC Dream Vectors) loaded with miR-
16 mimic and targeted against EGFR. The drug was designed
with the aim to restore the frequent down-expression of miR-
16 in MPM. Twenty-seven patients (with diagnosis of EGFR
positive MPM progressed after chemotherapy) were enrolled
between September 2014 and November 2016 (26 patients were
treated). The investigators found that 5 × 109 intravenous
TargomiRs once weekly was the maximum tolerated dose. The
most common adverse events were transient lymphopenia (96%),
hypophosphataemia (65%), and increased transaminase levels
(23%). Cardiac events (18%) occurred in five cases including one
case of ischaemia and one case of Takotsubo cardiomyopathy.
The drug showed early signs of activity. The median OS was 200
days (95% CI 94-358) with 5% of partial response, 68% of stable
disease, and 27% of progressive disease registered as best response
(80). The toxicity profile and the initial activity signs, make the
development of this drug interesting, especially in association
with chemotherapy and or immunotherapy.
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Sayeed et al. investigated the potential role of dietary
phytochemicals as possible preventive and/or therapeutic tool
in MPM in a very interesting review (81). Nevertheless, at the
present, only one dietary phytochemical (ursolic acid) (30) has
been shown to have miRNA regulatory activity in MPM. The
research in this field is at a very preliminary level and a completed
opinion cannot be expressed yet.
CONCLUSIONS
Our review strongly supports the idea that the detection,
quantization and analysis of miRNAs in MPM tissues and
biological fluid samples have a great potential both from
diagnostic and therapeutic point of view. Nevertheless, the
literature analysis showed multiple limitations in the discussed
studies.
One potential explanation for the strong diversity of data
obtained from different studies is the heterogeneity in the
quantification methods and in the type of samples and controls
used. In particular, the adoption of various technical approaches
among the analyzed studies, based on extremely different
chemistries, represent a limitation for the identification of
miRNA candidates with a consistent differential expression in
diverse analyzed populations. It is desirable that the use of RNA
high throughput sequencing systems will provide more reliable
and reproducible data in future investigations, with a more clear
clinical application.
Furthermore, in some studies data are poorly defined and
some important information are not provided and/or the
statistical analysis is not adequate. In order to improve these
weaknesses, it is critical that future studies will use more uniform
controls for their quantitative evaluations. In particular, while
some studies involved normal healthy patients, others included
in the same control population patients affected from non-cancer
pulmonary disease or asbestos-exposed non-cancer patients.
This last approach might lead to misidentification (or lack of
identification) of microRNAs whose expression is also altered
in these pathological statuses. For these reasons, there is limited
reproducibility in the available results, which strongly affects the
possibility of meta-analysis of published studies.
Finally, future studies would strongly benefit from the
inclusion of additional clinic/pathological parameters of
the included patients, such as histotype, disease status,
and treatments. Stratification of patients based on these
additional parameters might allow a better characterization and
classification of MPMs.
However, despite these critical points, several miRNAs and/or
miRNA families able to modulate crucial cell functions such
as methylation, autophagy, apoptosis, proliferation, invasion,
migration, and chemo/radio-resistance have been recently
discovered and their knowledge has been deepened also in
MPM. The role of various miRNAs as diagnostic or prognostic
biomarkers in MPM has been confirmed in more than one study
and in some cases it is becoming more and more solid (miR-
16, miR-103, miR-126, miR-145, and miR-200c), and could pave
the way to their clinical testing, both as diagnostic/prognostic
markers, and as therapeutic agents.
Initial data on the use of miRNA replacement therapy
in humans are starting to be published and the preliminary
results in MPM patients are encouraging (82, 83). However,
these therapeutic approaches are still lacking appropriate
clinical validation, and several issues will have to be solved
before they could be considered for the clinical practice.
In particular, it is still unclear how miRNA-based therapies,
using mimics or inhibitors, could affect the physiology of
normal cells, and there is a still-unmet need of cancer-specific
delivery systems that could limit undesired effects of these
treatments.
In conclusion, this literature review, by highlighting the
extreme heterogeneity of studies analyzing the role ofmicroRNAs
in MPM, wants to urge a coordinated collaboration between the
main international groups working in this research field. In fact,
the future scenario of MPM patients will see relevant clinical
improvements only through coordinated efforts of multiple basic
and translational research studies.
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